GlassScriptPhysician profile
Marilyn Wallin
NPI 1750069092
$989.22
in general payments reported to CMS, 2019-2025
26 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $156 · 2024: $550 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138.19 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $94.93 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Abbvie INC. | $78.71 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $67.57 | 2023-2024 | |
| Gilead Sciences, INC. | $67.23 | 2025 | |
| Exact Sciences Corporation | $57.81 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $50.47 | 2024 | Uzedy |
| Ironshore Pharmaceuticals INC. | $38.79 | 2024 | |
| Pfizer INC. | $34.12 | 2023-2024 | |
| Lilly USA, LLC | $33.76 | 2024-2025 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $31.59 | 2025 | |
| Amgen INC. | $28.44 | 2023-2024 | Repatha |
| Indivior INC. | $25.35 | 2025 | Sublocade |
| Dexcom, INC. | $23.40 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $22.61 | 2023 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.85 | 2024 | Aptima |
| Glaxosmithkline, LLC. | $20.69 | 2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $20.39 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $19.96 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.99 | 2025 | Voquezna |
| Insulet Corporation | $17.30 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $16.47 | 2024 | Auvelity |
| Alnylam Pharmaceuticals INC. | $16.10 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $15.66 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $14.64 | 2023 | |
| Redhill Biopharma INC. | $14.20 | 2025 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Wallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.